AU5536794A - Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds - Google Patents

Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds

Info

Publication number
AU5536794A
AU5536794A AU55367/94A AU5536794A AU5536794A AU 5536794 A AU5536794 A AU 5536794A AU 55367/94 A AU55367/94 A AU 55367/94A AU 5536794 A AU5536794 A AU 5536794A AU 5536794 A AU5536794 A AU 5536794A
Authority
AU
Australia
Prior art keywords
sep
cis
ylmethoxy
ylmethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55367/94A
Other languages
English (en)
Inventor
Anthony Marfat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Publication of AU5536794A publication Critical patent/AU5536794A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU55367/94A 1992-10-21 1993-09-30 Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds Abandoned AU5536794A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96433792A 1992-10-21 1992-10-21
US964337 1992-10-21
PCT/US1993/009171 WO1994008996A1 (en) 1992-10-21 1993-09-30 Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds

Publications (1)

Publication Number Publication Date
AU5536794A true AU5536794A (en) 1994-05-09

Family

ID=25508435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55367/94A Abandoned AU5536794A (en) 1992-10-21 1993-09-30 Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds

Country Status (23)

Country Link
US (1) US5641789A (2)
EP (1) EP0665842A1 (2)
JP (1) JPH07508534A (2)
KR (1) KR950704309A (2)
CN (1) CN1090282A (2)
AP (1) AP9300578A0 (2)
AU (1) AU5536794A (2)
BR (1) BR9307277A (2)
CA (1) CA2146261A1 (2)
CZ (1) CZ100095A3 (2)
FI (1) FI934625A7 (2)
HR (1) HRP931297A2 (2)
HU (1) HUT68323A (2)
IL (1) IL107294A0 (2)
MA (1) MA23009A1 (2)
MX (1) MX9306528A (2)
NO (1) NO303224B1 (2)
PL (1) PL308474A1 (2)
RU (1) RU95109929A (2)
SI (1) SI9300554A (2)
TW (1) TW265335B (2)
WO (1) WO1994008996A1 (2)
ZA (1) ZA937782B (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539128A (en) * 1994-11-30 1996-07-23 Pfizer Inc. Processes and intermediates for preparing cis(+)3-[4,6-dihydroxy chroman-3-ylmethyl]-4-methoxyaniline
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
SK31399A3 (en) * 1996-09-16 2000-05-16 Pfizer Processes and intermediates for preparing substituted chromanol derivatives
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
GB9800039D0 (en) * 1998-01-02 1998-03-04 Univ Cardiff Benzyl and benzylidene tetralins and derivatives
RU2182004C1 (ru) * 2001-02-22 2002-05-10 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственный препарат для парентерального применения
JP4358515B2 (ja) * 2001-04-10 2009-11-04 タカラバイオ株式会社 治療剤
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
EP1579010A4 (en) * 2002-10-17 2010-07-21 Decode Genetics Ehf SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND METHODS OF TREATMENT
CA2539276A1 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20060210514A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin protection and moisturizing compositions and method of making the same
CN119912349B (zh) * 2023-10-31 2025-11-21 中国石油天然气股份有限公司 一种可降解凝胶用交联剂、制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059609A (en) * 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases

Also Published As

Publication number Publication date
MX9306528A (es) 1994-06-30
MA23009A1 (fr) 1994-07-01
CN1090282A (zh) 1994-08-03
TW265335B (2) 1995-12-11
HUT68323A (en) 1995-06-28
AP9300578A0 (en) 1995-04-07
FI934625L (fi) 1994-04-22
EP0665842A1 (en) 1995-08-09
IL107294A0 (en) 1994-01-25
KR950704309A (ko) 1995-11-17
BR9307277A (pt) 1999-05-11
HRP931297A2 (en) 1996-08-31
NO951506L (no) 1995-04-20
CA2146261A1 (en) 1994-04-28
FI934625A0 (fi) 1993-10-20
CZ100095A3 (en) 1995-11-15
SI9300554A (en) 1995-04-30
NO951506D0 (no) 1995-04-20
JPH07508534A (ja) 1995-09-21
ZA937782B (en) 1995-04-20
FI934625A7 (fi) 1994-04-22
US5641789A (en) 1997-06-24
PL308474A1 (en) 1995-08-07
HU9302969D0 (en) 1993-12-28
NO303224B1 (no) 1998-06-15
WO1994008996A1 (en) 1994-04-28
RU95109929A (ru) 1997-03-20

Similar Documents

Publication Publication Date Title
EP0665842A1 (en) Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds
JP3507494B2 (ja) タキキニン拮抗薬
EP1268466B1 (en) Decahydro-isoquinolines
US5843988A (en) Cyclopropachromencarboxylic acid derivatives
CA2176668C (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
JPH01157969A (ja) 置換クロマンおよび関連化合物
KR20020005767A (ko) 항균 화합물
EP3863755A1 (en) Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators
JP2006522796A (ja) ピペラジン誘導体レニン阻害剤
IL273339B1 (en) Griseofulvin compound and pharmaceutical use thereof
JP2026083313A (ja) テトラヒドロキノリン誘導体及びその医薬用途
MX2007015678A (es) Antagonistas y agonistas de piperazina-piperidina del receptor 5-ht-1a.
PT88781B (pt) Processo para a preparacao de tetralinas, cromanos e compostos relacionados substituiidos, uteis no tratamento da asma
EP3447045B1 (en) 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria
AU2002359378B8 (en) Isochroman compounds for treatment of CNS disorders
US20260083723A1 (en) Therapeutic agent or prophylactic agent for amyotrophic lateral sclerosis
AU4076693A (en) Heteroaromatic 5-hydroxytryptamine receptor agonists
JP2010514705A (ja) 置換酒石酸の誘導体及びβ−セクレターゼ阻害剤を調製するための使用
JP2001512491A (ja) 1−(イソキノリン−1−イル)−4−(1−フェニメチル)ピペラジン;ドーパミン受容体サブタイプ特異的リガンド
WO2023249105A1 (ja) 薬剤性心筋障害の治療剤又は予防剤
JPH02237988A (ja) イソオキサゾロピリジン系メバロノラクトン類
JP3281492B2 (ja) N−ヒドロキシウレア類
EP1909792B1 (en) Substituted piperidine derivatives as somatostatin sst1 receptor antagonists
JP2005513124A (ja) 新規なアミジン誘導体および製剤におけるそれらの使用
KR20010103188A (ko) 3-하이드록시크로멘-4-온 구조를 갖는 cdk 저해제